EN DE
Watch Organogenesis Holdings Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Organogenesis Holdings Inc (ORGO) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Organogenesis Holdings Inc stock $2.90, price $0.97, upside +200.0%, quality 56 out of 100. Rating: strongly undervalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US68621F1021

OH Organogenesis Holdings Inc logo Thin data Nov 11, 2026

Organogenesis Holdings Inc

ORGO · US

Cheap (67% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value $2.90 · Strongly undervalued 
Low debt 
Even on cautious assumptions the value is 140% above the price ($2.31). 
Quality 56/100 
Mixed Growth (revenue 5y +10.7 %/yr in USD) 
Loss over the last twelve months · -38.5% net margin (TTM) · fiscal year 2025 6.6% 
Mixed vs. peers (5/10) 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 18/100
Thin data 
Watch Organogenesis Holdings Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$17.06 $0.7560 Fair Value $2.90 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $0.7560 – $17.06 · fair‑value band $2.31 – $3.76 · the $0.9650 price screens below the $2.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Organogenesis Holdings in your weekly email

Every Wednesday you see whether Organogenesis Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

Show moreShow less

Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.

The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing.

In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products.

The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Stock analysis

Organogenesis Holdings Inc (ORGO) currently trades at $0.9650, while our model-based Fair Value estimate is $2.90, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $6.65 per share, and 15 of the 15 models we run sit above the $0.9650 price.

Bear case: the Asset-Based group reads lowest at $1.52, and 0 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: $2.31 (bear) to $3.76 (bull), the price of $0.9650 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Organogenesis Holdings Inc reported revenue of $563M in FY2025 versus $467M in FY2021, a compound +4.8%/yr. Reported net income was $37.0M in FY2025, compounding −20.8%/yr from FY2021.

Key figures

Market cap $124M Micro · P/S ratio 0.33 · EPS (TTM) $−1.33 · Net margin 6.6% · Return on equity −41.7% · Return on assets (EBIT) 6.6% (5-year average) · Operating margin −64.9% · Revenue (TTM) $352M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 85% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, ORGO screens cheaper than that median.

Fair Value models

Bear $2.31 Fair Value $2.90 Bull $3.76
Price $0.9650 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $1.47 $2.07 $2.86 77
EPV $2.50 $2.74 $2.93 74
ROIC Compounder $2.50 $2.74 $2.93 72
All 15 models by family
DCF Models
Owner Earnings $1.47 $2.07 $2.86 77
Earnings-Based
Graham-Dodd $1.94 $8.49 $11.62 64
Lynch FV $2.19 $3.13 $4.07 61
PEG = 1.0 $2.19 $3.13 $4.07 57
EPV $2.50 $2.74 $2.93 74
Multiples
P/E Multiple $4.71 $6.28 $7.85 63
P/S Multiple $3.64 $4.85 $6.06 58
P/B Multiple $10.30 $13.73 $17.16 55
EV/EBIT $5.19 $7.02 $8.84 66
EV/EBITDA $6.40 $8.63 $10.86 67
EV/Revenue $3.62 $5.29 $6.97 53
Asset-Based
NCAV (Graham) $1.00 $1.52 $1.90 54
Economic Profit
Residual Income $2.42 $2.45 $2.65 71
ROIC Compounder $2.50 $2.74 $2.93 72
Growth Earnings
Growth-Adj P/E $3.72 $5.31 $6.91 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 58
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 53
Does it invest with discipline instead of growing at any price?
Low Volatility 13
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 93
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyMichael Joseph DriscollDirector10,000 shares at $2.67$26,700Mar 9, 2026
  • BuyArthur S LeibowitzDirector5,000 shares at $2.68$13,400Mar 9, 2026
  • SaleGlenn H NussdorfDirector2× since Nov 24, 2025: 500,000 shares, avg. $5.24$2.6MDec 16, 2025

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 12, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Start year 2020 (pandemic). Over 10 years: +19.0% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−10.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 10%

Watch ORGO, get fair value alerts →

Compare Organogenesis Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside +200.0% · Top 25%
Profitability
Return on assets 6.2% · Above median
Net margin (12 months) −38.5% · Bottom 25%
Operating margin (12 months) −64.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −69.9% · Bottom 25%
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.29× · Cheapest 25%
P/S (12 months) 0.35× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.96 $113.53 +37% vs ORGO
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.93 ¥53.04 +11% vs ORGO
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,885 ₹1,983 +5% vs ORGO
Haleon plc HLN $9.09 $8.62 −5% vs ORGO
Merck KGaA MRK €148.15 €108.83 −27% vs ORGO
Galderma Group GALD CHF 194.40 CHF 111.92 −42% vs ORGO
Takeda Pharmaceutical Company TAK $21.12 $11.34 −46% vs ORGO
Teva Pharmaceutical Industries Limited TEVA $43.65 $20.74 −52% vs ORGO
Sandoz Group SDZ CHF 86.90 CHF 40.54 −53% vs ORGO
Divi's Laboratories Limited DIVISLAB ₹11,485 ₹1,567 −86% vs ORGO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Organogenesis Holdings Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Organogenesis Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/ORGO

Frequently asked questions

Is Organogenesis Holdings Inc (ORGO) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of $2.90 versus a price of $0.9650, about +200% upside (undervalued).
What is the fair value of ORGO?
Our model-based fair value for Organogenesis Holdings Inc is $2.90 (as of Nov 11, 2026), built from audited fundamentals. The current price: $0.9650.
What is the quality score of ORGO?
Organogenesis Holdings Inc has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Organogenesis Holdings Inc (ORGO)?
Our model-based price target is the fair value of $2.90 (as of Nov 11, 2026) from 15 valuation models. Cautious scenario $2.31, optimistic scenario $3.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Organogenesis Holdings Inc stock forecast for 2026?
Our models put fair value at $2.90, about +200% upside versus a price of $0.9650 (undervalued). Cautious scenario $2.31, optimistic scenario $3.76. The calculation is refreshed regularly with new filings.
What is the revenue of Organogenesis Holdings Inc (ORGO)?
Organogenesis Holdings Inc reported trailing-twelve-month revenue of about $352M (latest available figure, as of Nov 11, 2026).
Does Organogenesis Holdings Inc pay a dividend?
Organogenesis Holdings Inc does not currently pay a dividend.
What is the intrinsic value of Organogenesis Holdings Inc (ORGO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Organogenesis Holdings Inc it is $2.90 per share (as of Nov 11, 2026), against a price of $0.9650. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Organogenesis Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, ORGO trades below its calculated fair value: price $0.9650, fair value $2.90, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORGO?
No. The price is what the market pays today ($0.9650); the fair value is what the company's own numbers justify ($2.90). For Organogenesis Holdings Inc the two are $1.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Organogenesis Holdings Inc worth?
The market values Organogenesis Holdings Inc at about $124M (market capitalisation, as of Nov 11, 2026). Per share that is $0.9650; our models calculate a fair value of $2.90 per share.
What do the bullish and bearish scenarios say about ORGO?
Our models span a range for Organogenesis Holdings Inc: cautious scenario $2.31, base $2.90, optimistic $3.76 per share (as of Nov 11, 2026, price $0.9650). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Organogenesis Holdings Inc (ORGO)?
Balance-sheet figures for Organogenesis Holdings Inc (as of Nov 11, 2026): return on equity −41.7%, debt of 0.14 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is ORGO from its 52-week high?
Organogenesis Holdings Inc trades at $0.9650, about 85% below its 52-week high of $6.48 and 28% above the low of $0.7560 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of $2.90 is for.
Which stocks are comparable to Organogenesis Holdings Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Organogenesis Holdings Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $0.9650, calculated fair value $2.90 (+200%), Quality Score 56/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ORGO calculated?
We run Organogenesis Holdings Inc through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $2.90 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Organogenesis Holdings Inc currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Organogenesis Holdings Inc (ORGO)?
The closing price on Nov 12, 2026 was $0.9650. Our model-based fair value is $2.90, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Organogenesis Holdings Inc right now?
The price is below even our cautious bear case ($2.31). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Organogenesis Holdings Inc

How large is the market capitalisation of Organogenesis Holdings Inc (ORGO)?
The market capitalisation of Organogenesis Holdings Inc is $124M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Organogenesis Holdings Inc (ORGO)?
The price-to-sales ratio of Organogenesis Holdings Inc is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Organogenesis Holdings Inc (ORGO)?
Earnings per share at Organogenesis Holdings Inc are $−1.33. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Organogenesis Holdings Inc (ORGO)?
The net margin of Organogenesis Holdings Inc is 6.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Organogenesis Holdings Inc (ORGO)?
The return on equity (ROE) of Organogenesis Holdings Inc is −41.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Organogenesis Holdings Inc (ORGO)?
On an EBIT basis the return on assets of Organogenesis Holdings Inc is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Organogenesis Holdings Inc (ORGO)?
The operating margin of Organogenesis Holdings Inc is −64.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Organogenesis Holdings Inc (ORGO)?
Revenue at Organogenesis Holdings Inc is growing −69.9% versus a year earlier (3y avg +7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Organogenesis Holdings Inc (ORGO)?
Earnings per share at Organogenesis Holdings Inc are growing +555% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Organogenesis Holdings Inc (ORGO) generate?
The free cash flow of Organogenesis Holdings Inc is −$24.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Organogenesis Holdings Inc (ORGO) carry?
The net debt of Organogenesis Holdings Inc is $39.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Organogenesis Holdings Inc in the live analysis

One click puts Organogenesis Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.